Visão geral da empresa
Phaos Technology Holdings (Cayman) Limited, operating primarily through its Singapore-based subsidiary Phaos Technology Pte. Ltd., focuses on the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products designed to enable users to view live and still imagery with high precision. The company operates within the Healthcare sector, specifically the Medical Devices industry, where its activities contribute to diagnostic imaging and research capabilities essential for medical advancements. As a public entity with a market capitalization of $21.93M and an annual revenue of $167,707, the organization maintains a lean operational structure supported by a workforce of 25 employees. These valuation and revenue figures indicate that the company is a small-cap entity with limited market penetration relative to established industry peers, reflecting a stage of development where product commercialization and market expansion are critical priorities rather than established cash flow generation.
Saúde financeira
The company reported a trailing twelve-month revenue of $167,707 against a net income of $-5,137,064, revealing a significant gap between top-line generation and profitability that points to a cost structure heavily weighted toward research, development, and operational overheads not yet offset by scalable revenue. The reported EBITDA stands at $-3,869,313, further confirming that the business is currently operating at a loss before interest, taxes, depreciation, and amortization. Free cash flow is reported at $-1,657,362, indicating that the company is consuming more cash than it generates from operations, which limits its financial flexibility and reliance on external capital injections. Analysis of the three primary margins shows a Gross Margin of 22.1%, suggesting that product costs are contained relative to sales, yet this is negated by an Operating Margin of -1897.8% and a Profit Margin of 0.0%, highlighting severe inefficiencies or one-time costs impacting the bottom line. The balance sheet shows cash holdings of $177,660 against total debt of $3.26M, resulting in a debt-to-equity ratio listed as N/A due to the negative equity position, which suggests a leveraged and distressed financial state rather than a conservative posture. The Current Ratio is 0.40, indicating that current assets are less than half of current liabilities, which signals potential short-term liquidity challenges in meeting immediate obligations. Furthermore, the Return on Equity is -1073.1% and the Return on Assets is -71.2%, metrics that reveal management has not yet been effective in generating positive returns on the capital invested in the company.
Avaliação de valorização
The trailing P/E ratio and forward P/E ratio are both listed as N/A, as the negative net income prevents the calculation of a standard earnings multiple, implying that traditional earnings-based valuation models are not applicable given the company's current loss-making status. The Price to Book ratio is -27.23, a negative figure that indicates the market value of the company is significantly below its book value, often seen in distressed situations or entities with substantial intangible assets not fully reflected on the balance sheet. The Price to Sales ratio is 130.77, a metric suggesting that investors are valuing the company based on revenue potential rather than profitability, while the EV/EBITDA stands at -11.44, reinforcing the lack of positive cash conversion relative to enterprise value. The stock price has fluctuated between a 52-week low of $0.53 and a 52-week high of $7.39, meaning the current price sits within this range but reflects high volatility typical of micro-cap stocks with speculative characteristics. The Beta value is listed as N/A, which prevents a direct comparison of price volatility relative to the broader market, though the wide spread between the 52-week high and low suggests the stock is sensitive to market sentiment and investor sentiment rather than broad market movements.
Growth & Income
The company experienced a revenue growth year-over-year of -93.1%, while earnings growth is listed as N/A due to the absence of prior period positive earnings for comparison; this contraction indicates a severe decline in top-line performance over the last year. As the company does not pay dividends, the dividend yield and payout ratio are both N/A and 0.0% respectively, signifying that all available resources are theoretically directed toward operations rather than shareholder distributions. In the absence of dividend payments, the company effectively reinvests its limited earnings or capital into growth initiatives, although the negative net income suggests these reinvestments are currently failing to generate sufficient profit. The overall growth and income profile is characterized by significant revenue contraction and a complete lack of dividend income, positioning the asset as a high-risk, non-income-generating investment suitable only for speculative portfolios willing to accept the possibility of total capital erosion.